FINWIRES · TerminalLIVE
FINWIRES

Top Midday Stories: TSMC Earnings, Guidance Top Estimates But Shares Fall; PepsiCo Shares Rise Following Q1 Earnings Report

By

All three major US stock indexes were up in late-morning trading Thursday, as investors take in updates on the war in Iran as well as the latest large-company earnings reports.

In company news, Taiwan Semiconductor Manufacturing (TSM), or TSMC, reported Q1 earnings Thursday of 22.08 New Taiwan dollars ($0.70) per diluted share, up from NT$13.94 a year earlier and above the FactSet consensus analyst estimate of NT$20.92. First-quarter net revenue was NT$1.134 trillion, up from NT$839.25 billion a year ago and above the FactSet consensus of NT$1.121 trillion. For Q2, the chipmaker said it expects net revenue of $39 billion to $40.2 billion, above the FactSet consensus of $38.09 billion. TSMC shares were down 1.9% around midday.

PepsiCo (PEP) reported fiscal Q1 core earnings Thursday of $1.61 per diluted share, up from $1.48 a year earlier and above the FactSet consensus of $1.54. Fiscal Q1 net revenue was $19.44 billion, up from $17.92 billion a year ago and above the FactSet consensus of $18.95 billion. For fiscal 2026, PepsiCo said it continues to expect core constant currency EPS growth of 4% to 6% and organic revenue growth of between 2% and 4%. PepsiCo shares were up 2.1%.

Abbott Laboratories (ABT) reported Q1 adjusted earnings Thursday of $1.15 per diluted share, up from $1.09 a year earlier and above the FactSet consensus of $1.14. First-quarter net sales were $11.16 billion, up from $10.36 billion a year ago and above the FactSet consensus of $11.00 billion. For Q2, Abbott said it expected adjusted diluted EPS of $1.25 to $1.31, below the FactSet consensus of $1.36. For full-year 2026, the company said it expects adjusted EPS of $5.38 to $5.58, down from its prior guidance of $5.55 to $5.80 and below the FactSet consensus of $5.60. Full-year 2026 comparable sales are expected to grow 6.5% to 7.5%, the company said. Abbott shares were down 4.4%.

Charles Schwab (SCHW) reported Q1 adjusted earnings Thursday of $1.43 per diluted share, up from $1.04 a year earlier and above the FactSet consensus of $1.40. First-quarter net revenue was $6.48 billion, up from $5.60 billion a year ago but below the FactSet consensus of $6.50 billion. The company also said Thursday it will launch a spot cryptocurrency trading service for retail customers in the coming weeks. For a fee of 75 basis points per transaction, the platform will provide direct trading of bitcoin and ethereum alongside traditional investments, the company said. Shares of Schwab were down 4.8%.

Stellantis (STLA) and Microsoft (MSFT) said Thursday they have signed a five-year strategic collaboration deal to co-develop advanced artificial intelligence, cybersecurity and engineering capabilities for the automaker's vehicles. Separately, Stellantis is planning a 100-million-euro ($117.9 million) investment to update its Poissy assembly plant near Paris, Bloomberg reported Thursday. The company will continue making vehicles at the facility through at least the end of 2028, the report said. Stellantis shares were down 0.8%, while Microsoft shares were up 1.6%.

Oracle (ORCL) said Thursday it plans to expand its multicloud networking capabilities to provide high-performance connectivity between Oracle Cloud Infrastructure and Amazon's (AMZN) Amazon Web Services. Oracle shares were up 4.1%, while Amazon shares were down 0.3%.

Sales of Tesla's (TSLA) Cybertruck were boosted by purchases from Elon Musk's other companies, Bloomberg reported Thursday, citing S&P Global Mobility registration data. Tesla shares were down 1.1%.

Price: $368.08, Change: $-7.02, Percent Change: -1.87%

Related Articles

Wire

Savara Says FDA Extended Review Period for Molgramostim Inhalation Solution Application

Savara (SVRA) said late Wednesday the US Food and Drug Administration has extended the review period for molgramostim biologics license application in autoimmune pulmonary alveolar proteinosis, a rare lung disease, by three months.The new prescription drug user fee act target action date for the inhalation solution is Nov. 22, the company said.The FDA did not cite any efficacy, safety, or manufacturing concerns, the company said, adding that the FDA determined that the responses to recent information requests represented a significant amendment to the application.

$SVRA
Wire

Euroseas Extends EM Kea Charter for Three Years at Higher Daily Rate

Euroseas (ESEA) extended a charter contract for its feeder containership EM Kea by three years at a gross daily rate of $30,000.The charter is set to begin on July 14 and reflects nearly a 60% increase over the vessel's current rate, the company said Wednesday in a statement.Euroseas expects the charter to generate about $22.5 million in EBITDA over the minimum contracted period.The company's shares fell 2% in after-hours trading.

$ESEA
Wire

Voyager Wins NASA Order for Seventh Private Astronaut Mission to International Space Station

Voyager Technologies (VOYG) said late Wednesday it has signed an order with National Aeronautics and Space Administration for the seventh private astronaut mission to the International Space Station, with a launch planned no earlier than 2028.The mission, dubbed VOYG-1, supports NASA's strategy to shift low-Earth orbit operations to the private sector by enabling commercial partners to deliver human spaceflight services, the company said.

$VOYG
Top Midday Stories: TSMC Earnings, Guidance Top Estimates But Shares Fall; PepsiCo Shares Rise Following Q1 Earnings Report | FINWIRES